Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Description No. ───────────────────────────────────────────────────────────────────────────────────────────────── 10.1 Amendment Agreement relating to the L.I.A. Pure Capital Ltd. Warrant 10.2 Form of Amended and Restated L.I.A. Pure Capital Ltd.…
Filed Oct 6, 2026Accepted Oct 6, 2026, 9:30 AM EDTCIK 1789192Accession 0001493152-26-045885
We are focused on sustainable operations in various industries such as biotechnology and solar projects. Our activities are advancing innovative drug development solutions through MitoCareX to improve treatments for cancer and inflammatory metabolic diseases.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 9.01Item 9.01 - Financial Statements and Exhibits
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
Exhibit Description
No.
─────────────────────────────────────────────────────────────────────────────────────────────────
10.1 Amendment Agreement relating to the L.I.A. Pure Capital Ltd. Warrant
10.2 Form of Amended and Restated L.I.A. Pure Capital Ltd. Warrant
10.3 Form of Amendment Agreement relating to June 15, 2026 Private Placement Warrants
10.4 Form of Amended and Restated June 15, 2026 Private Placement Warrant
10.5 Form of Amendment Agreement relating to June 24, 2026 Private Placement Warrants
10.6 Form of Amended and Restated June 24, 2026 Private Placement Warrant
104 Cover
Page Interactive Data File (embedded within the Inline XBRL document)